GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                                     
                             Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: TH-4000E is the active compound generated from the prodrug tarloxotinib (TH-4000).
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| Bioactivity Comments | 
| To date (Nov 2016) data for this drug has been published in abstract form only (Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial and Abstract e13548: TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC. We await publication in a peer reviewed article. |